Table 1.
Some clinical data on the groups of subjects studied. Median and 25th and 75th percentile values are reported in brackets
| Group 1 n = 59 |
Group 2 n = 30 |
Group 3 n = 141 |
Significance P | |
|---|---|---|---|---|
| Age (years) | 41.2 ± 7.5 (43; 37–47) | 42.4 ± 9.2 (45; 40–49) | 33.1 ± 10.1 (33; 24–42) | < 0.0001; a |
| Mother’s age on menopause (years) | 51.0 ± 4.2 (51; 50–54) | 51.1 ± 4.2 (51; 49–55) | 50.1 ± 4.2 (51; 48–52) | 0.57 |
| Time since primary treatments (years) | 7.2 ± 6.8 (5: 2–9) | 4.6 ± 4.1 (3; 1–7) | n.a. | 0.07 |
| BMI (kg/m2) | 25.3 ± 6.0 (23.5; 21.6–27.0) | 24.2 ± 6.0 (23.5; 21.6–27.0) | 24.5 ± 6.5 (23.8; 21.0–25.3) | 0.45 |
| Cumulative RAI activity (mCi) | 100.1 ± 117.4 (80; 60–100) | n.a. | n.a. | – |
| Cured (%) / Biochemical disease (%) | 97/3 | 100/0 | n.a. | 0.55 |
| L-T4 dosage (μg/week) | 859.1 ± 157.3 (825; 775–925) | 741.3 ± 148.4 (725; 644–875) | n.a. | 0.001 |
| TSH (mIU/l) | 0.46 ± 0.83 (0.17; 0.04–0.42) | 1.69 ± 1.78 (1.37; 0.25–2.31) | 2.35 ± 1.79 (2.11; 1.23–2.81) | < 0.0001; b, c |
| f-T4 (pmol/l) | 20.5 ± 4.9 (20.7; 18.1–23.2) | 16.5 ± 3.9 (16.4; 15.2–19.0) | 13.8 ± 3.3 (13.4; 11.4–16.7) | < 0.0001; d, e, f |
| Tg (μg/l) | 0.24 ± 0.47 (0.20; 0.04–0.20) | 1.32 ± 3.20 (0.20; 0.09–0.67) | n.d. | 0.01 |
| TgAb positive (%) | 2 | 4 | n.d. | 0.17 |
(When ANOVA was significant, differences among groups were evaluated by means of Dunn’s test. Age: (a) group 3 vs group 1 and group 2, both P < 0.0001. TSH: (b) group 1 vs group 2, P = 0.03; (c) group 1 vs group 3, P < 0.0001. Free-T4: (d) group 1 vs group 2, P = 0.003; (e) group 1 vs group 3, P < 0.0001; (f) group 2 vs group 3, P = 0.003. Evaluation not applicable: n.a.; evaluation not done: n.d.)